{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:58:34Z","timestamp":1790456314188,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00535-026-02481-7","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:31:00Z","timestamp":1784349060000},"page":"1471-1482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes of lean metabolic dysfunction-associated steatotic liver disease by phenotypic subtypes"],"prefix":"10.1007","volume":"61","author":[{"given":"Chia-Chih","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Hsing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsing-Tao","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"issue":"2","key":"2481_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jama.2025.19615","volume":"335","author":"H Tilg","year":"2026","unstructured":"Tilg H, Petta S, Stefan N, Targher G. Metabolic dysfunction-associated steatotic liver disease in adults: a review. JAMA. 2026;335(2):163\u201374.","journal-title":"JAMA"},{"issue":"7","key":"2481_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher G, Valenti L, Byrne CD. Metabolic dysfunction\u2013associated steatotic liver disease. N Engl J Med. 2025;393(7):683\u201398.","journal-title":"N Engl J Med"},{"issue":"2","key":"2481_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","volume":"13","author":"N Stefan","year":"2025","unstructured":"Stefan N, Yki-J\u00e4rvinen H, Neuschwander-Tetri BA. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol. 2025;13(2):134\u201348.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2481_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s00535-016-1264-3","volume":"52","author":"WK Seto","year":"2017","unstructured":"Seto WK, Yuen MF. Nonalcoholic fatty liver disease in Asia: emerging perspectives. J Gastroenterol. 2017;52(2):164\u201374.","journal-title":"J Gastroenterol"},{"issue":"11","key":"2481_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.70136","volume":"43","author":"X Fang","year":"2025","unstructured":"Fang X, Xu C, Lu J, Zhuang R, Xu X, Wei X. Lean metabolic dysfunction-associated steatotic liver disease: a wolf in sheep\u2019s clothing. Cell Biochem Funct. 2025;43(11):e70136.","journal-title":"Cell Biochem Funct"},{"issue":"1","key":"2481_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/HEP.0000000000000329","volume":"78","author":"O Nabi","year":"2023","unstructured":"Nabi O, Lapidus N, Boursier J, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study). Hepatology. 2023;78(1):272\u201383.","journal-title":"Hepatology"},{"issue":"1","key":"2481_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12072-022-10436-2","volume":"17","author":"AD Dao","year":"2023","unstructured":"Dao AD, Nguyen VH, Ito T, Cheung R, Nguyen MH. Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States. Hepatol Int. 2023;17(1):225\u201336.","journal-title":"Hepatol Int"},{"issue":"8","key":"2481_CR8","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1111\/jgh.17015","volume":"40","author":"L Ghani","year":"2025","unstructured":"Ghani L, Aboona MB, Faulkner CS, et al. Increased mortality among lean versus non-lean adults with MASLD: a multicenter study. J Gastroenterol Hepatol. 2025;40(8):1919\u201325.","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"2481_CR9","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1016\/j.cgh.2022.11.019","volume":"21","author":"J Ha","year":"2023","unstructured":"Ha J, Yim SY, Karagozian R. Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(10):2496-2507.e2495.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2481_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep4.1124","volume":"2","author":"H Hagstr\u00f6m","year":"2018","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long\u2010term follow\u2010up study. Hepatol Commun. 2018;2(1):48\u201357.","journal-title":"Hepatol Commun"},{"key":"2481_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-336127","author":"Z Huo","year":"2025","unstructured":"Huo Z, Chen Y, Huang Y, et al. Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts. Gut. 2025. https:\/\/doi.org\/10.1136\/gutjnl-2025-336127.","journal-title":"Gut"},{"issue":"6","key":"2481_CR12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00535-024-02093-z","volume":"59","author":"SI Wakabayashi","year":"2024","unstructured":"Wakabayashi SI, Tamaki N, Kimura T, Umemura T, Kurosaki M, Izumi N. Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease. J Gastroenterol. 2024;59(6):494\u2013503.","journal-title":"J Gastroenterol"},{"issue":"9","key":"2481_CR13","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/apt.17424","volume":"57","author":"K Wijarnpreecha","year":"2023","unstructured":"Wijarnpreecha K, Li F, Lundin SK, et al. Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities. Aliment Pharmacol Ther. 2023;57(9):1014\u201327.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2481_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2024.101288","volume":"29","author":"W Wongtrakul","year":"2024","unstructured":"Wongtrakul W, Charatcharoenwitthaya N, Charatcharoenwitthaya P. Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: an updated meta-analysis. Ann Hepatol. 2024;29(3):101288.","journal-title":"Ann Hepatol"},{"key":"2481_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-025-09710-4","author":"A Gade","year":"2025","unstructured":"Gade A, Papudesi BN, Joseph S. Clinical outcomes in acute decompensated metabolic dysfunction-associated steatotic liver disease cirrhosis: the role of BMI in mortality, readmission, and hospital stay. J Gen Intern Med. 2025. https:\/\/doi.org\/10.1007\/s11606-025-09710-4.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"2481_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/hep.26672","volume":"59","author":"AL Birkenfeld","year":"2014","unstructured":"Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59(2):713\u201323.","journal-title":"Hepatology"},{"issue":"2","key":"2481_CR17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","volume":"68","author":"A Lonardo","year":"2018","unstructured":"Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335\u201352.","journal-title":"J Hepatol"},{"issue":"1","key":"2481_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jhep.2020.02.028","volume":"73","author":"J Ampuero","year":"2020","unstructured":"Ampuero J, Aller R, Gallego-Dur\u00e1n R, et al. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. J Hepatol. 2020;73(1):17\u201325.","journal-title":"J Hepatol"},{"issue":"4","key":"2481_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","volume":"7","author":"N Stefan","year":"2019","unstructured":"Stefan N, H\u00e4ring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7(4):313\u201324.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2481_CR20","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.2337\/db22-0933","volume":"72","author":"S Sako","year":"2023","unstructured":"Sako S, Takeshita Y, Takayama H, et al. Trajectories of liver fibrosis and gene expression profiles in nonalcoholic fatty liver disease associated with diabetes. Diabetes. 2023;72(9):1297\u2013306.","journal-title":"Diabetes"},{"key":"2481_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21113863","author":"H Fujii","year":"2020","unstructured":"Fujii H, Kawada N, Japan Study Group Of Nafld J-N. The role of insulin resistance and diabetes in nonalcoholic fatty liver disease. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21113863.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2481_CR22","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/liv.15880","volume":"44","author":"MB Aboona","year":"2024","unstructured":"Aboona MB, Faulkner C, Rangan P, et al. Disparities among ethnic groups in mortality and outcomes among adults with MASLD: a multicenter study. Liver Int. 2024;44(6):1316\u201328.","journal-title":"Liver Int"},{"issue":"6","key":"2481_CR23","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v17.i6.107364","volume":"17","author":"HN Jung","year":"2025","unstructured":"Jung HN, Heo JH, Roh E, et al. Risk of hepatocellular carcinoma according to body mass index and waist circumference in nonalcoholic fatty liver disease. World J Gastrointest Oncol. 2025;17(6):107364.","journal-title":"World J Gastrointest Oncol"},{"key":"2481_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155222","volume":"133","author":"GE Chung","year":"2022","unstructured":"Chung GE, Jeong S-M, Cho EJ, et al. Association of fatty liver index with all-cause and disease-specific mortality: a nationwide cohort study. Metabolism. 2022;133:155222.","journal-title":"Metabolism"},{"issue":"6","key":"2481_CR25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.4254\/wjh.v16.i6.871","volume":"16","author":"R Wong","year":"2024","unstructured":"Wong R, Yuan LY. Sarcopenia and metabolic dysfunction associated steatotic liver disease: time to address both. World J Hepatol. 2024;16(6):871\u20137.","journal-title":"World J Hepatol"},{"key":"2481_CR26","doi-asserted-by":"publisher","first-page":"6297651","DOI":"10.1155\/2017\/6297651","volume":"2017","author":"Y Zhai","year":"2017","unstructured":"Zhai Y, Xiao Q. The common mechanisms of sarcopenia and NAFLD. Biomed Res Int. 2017;2017:6297651.","journal-title":"Biomed Res Int"},{"issue":"11","key":"2481_CR27","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1016\/j.cgh.2023.02.013","volume":"21","author":"M Harring","year":"2023","unstructured":"Harring M, Golabi P, Paik JM, et al. Sarcopenia among patients with nonalcoholic fatty liver disease (NAFLD) Is associated with advanced fibrosis. Clin Gastroenterol Hepatol. 2023;21(11):2876-2888.e2875.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"2481_CR28","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.clnu.2024.07.006","volume":"43","author":"X Li","year":"2024","unstructured":"Li X, He J, Sun Q. The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Clin Nutr. 2024;43(9):2005\u201316.","journal-title":"Clin Nutr"},{"issue":"2","key":"2481_CR29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.cgh.2022.01.020","volume":"21","author":"YC Hsieh","year":"2023","unstructured":"Hsieh YC, Joo SK, Koo BK, et al. Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression. Clin Gastroenterol Hepatol. 2023;21(2):388-397.e310.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2481_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100963","volume":"6","author":"G Henin","year":"2024","unstructured":"Henin G, Loumaye A, Leclercq IA, Lanthier N. Myosteatosis: diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease. JHEP Rep. 2024;6(2):100963.","journal-title":"JHEP Rep"},{"issue":"2","key":"2481_CR31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jhep.2021.02.037","volume":"75","author":"M Nachit","year":"2021","unstructured":"Nachit M, Kwanten WJ, Thissen J-P, et al. Muscle fat content is strongly associated with NASH: a longitudinal study in patients with morbid obesity. J Hepatol. 2021;75(2):292\u2013301.","journal-title":"J Hepatol"},{"issue":"3","key":"2481_CR32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jhep.2024.08.024","volume":"82","author":"Q Zhong","year":"2025","unstructured":"Zhong Q, Zhou R, Huang Y-N, et al. Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases. J Hepatol. 2025;82(3):427\u201337.","journal-title":"J Hepatol"},{"key":"2481_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000861","author":"S Naimimohasses","year":"2022","unstructured":"Naimimohasses S, O\u2019Gorman P, McCormick E, et al. Prevalence of frailty in patients with non-cirrhotic non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2022. https:\/\/doi.org\/10.1136\/bmjgast-2021-000861.","journal-title":"BMJ Open Gastroenterol"},{"key":"2481_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/nu17193128","author":"MS Iuorio","year":"2025","unstructured":"Iuorio MS, Lelli D, Bandinelli S, Ferrucci L, Pedone C, Antonelli Incalzi R. Total cholesterol and mortality in older adults: a sex-stratified cohort study. Nutrients. 2025. https:\/\/doi.org\/10.3390\/nu17193128.","journal-title":"Nutrients"},{"key":"2481_CR35","unstructured":"European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O, et al. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542."},{"issue":"5","key":"2481_CR36","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835.","journal-title":"Hepatology"},{"issue":"9","key":"2481_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03003-w","volume":"11","author":"P Rada","year":"2020","unstructured":"Rada P, Gonz\u00e1lez-Rodr\u00edguez \u00c1, Garc\u00eda-Monz\u00f3n C, Valverde \u00c1M. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis. 2020;11(9):802.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2481_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3350\/cmh.2022.0237","volume":"29","author":"KC Lee","year":"2023","unstructured":"Lee KC, Wu PS, Lin HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol. 2023;29(1):77\u201398.","journal-title":"Clin Mol Hepatol"},{"issue":"7","key":"2481_CR39","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1161\/HYPERTENSIONAHA.122.17982","volume":"79","author":"E Muzurovi\u0107","year":"2022","unstructured":"Muzurovi\u0107 E, Peng CC-H, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors. Hypertension. 2022;79(7):1319\u201326.","journal-title":"Hypertension"},{"issue":"4","key":"2481_CR40","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691\u2013702.","journal-title":"Gut"},{"key":"2481_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.09.003","author":"M Dukewich","year":"2025","unstructured":"Dukewich M, Dodge JL, Yuan L, Terrault NA. Differential effects of cardiometabolic risk factors on all-cause mortality in United States adults with metabolic dysfunction-associated steatotic liver disease (MASLD). Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2025.09.003.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2481_CR42","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.dld.2024.11.002","volume":"57","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Wang Y, Liu S, Zhu S, Li P, Wu S. Mortality risk associated with MASLD, MASLD type and different cardiometabolic risk factors in IBD patients: a long-term prospective cohort study. Dig Liver Dis. 2025;57(3):744\u201352.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"2481_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101388","volume":"7","author":"H Park","year":"2025","unstructured":"Park H, Cheuk-Fung Yip T, Yoon EL, et al. Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: a population-based multi-cohort study. JHEP Rep. 2025;7(6):101388.","journal-title":"JHEP Rep"},{"issue":"4","key":"2481_CR44","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cgh.2023.04.017","volume":"22","author":"R Sharma","year":"2024","unstructured":"Sharma R, Simon TG, Hagstr\u00f6m H, et al. Statins are associated with a decreased risk of severe liver disease in individuals with noncirrhotic chronic liver disease. Clin Gastroenterol Hepatol. 2024;22(4):749-759.e719.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2481_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101313","volume":"7","author":"B Yun","year":"2025","unstructured":"Yun B, Park H, Lee J, Kim BK, Yoon J-H. Statin use and liver-related prognosis among patients with MASLD. JHEP Rep. 2025;7(4):101313.","journal-title":"JHEP Rep"},{"issue":"4","key":"2481_CR46","doi-asserted-by":"publisher","first-page":"98543","DOI":"10.5493\/wjem.v14.i4.98543","volume":"14","author":"ZI Tarar","year":"2024","unstructured":"Tarar ZI, Farooq U, Inayat F, et al. Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. World J Exp Med. 2024;14(4):98543.","journal-title":"World J Exp Med"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02481-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02481-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02481-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:02:36Z","timestamp":1790452956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02481-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2481"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02481-7","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that there was no conflict of interest. There is no conflict of interest, financial, professional or otherwise, between the authors of this study.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Chi Mei Hospital institutional review board approved this TriNetX database study (approval number: 11402-E02) and waived the requirement for informed consent since the research used only aggregated statistical data from de-identified sources.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}